Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
Int J Mol Sci ; 24(24)2023 Dec 15.
Article in English | MEDLINE | ID: mdl-38139350

ABSTRACT

The number of people affected by cancer and antibiotic-resistant bacterial infections has increased, such that both diseases are already seen as current and future leading causes of death globally. To address this issue, based on a combined in silico and in vitro approach, we explored the anticancer potential of known antibacterials with a thiazolidinedione-thiosemicarbazone (TZD-TSC) core structure. A cytotoxicity assessment showed encouraging results for compounds 2-4, with IC50 values against T98G and HepG2 cells in the low micromolar range. TZD-TSC 3 proved to be most toxic to cancer cell lines, with IC50 values of 2.97 ± 0.39 µM against human hepatoma HepG2 cells and IC50 values of 28.34 ± 2.21 µM against human glioblastoma T98G cells. Additionally, compound 3 induced apoptosis and showed no specific hemolytic activity. Furthermore, treatment using 3 on cancer cell lines alters these cells' morphology and further suppresses migratory activity. Molecular docking, in turn, suggests that 3 would have the capacity to simultaneously target HDACs and PPARγ, by the activation of PPARγ and the inhibition of both HDAC4 and HDAC8. Thus, the promising preliminary results obtained with TZD-TSC 3 represent an encouraging starting point for the rational design of novel chemotherapeutics with dual antibacterial and anticancer activities.


Subject(s)
Antineoplastic Agents , Thiazolidinediones , Thiosemicarbazones , Humans , Structure-Activity Relationship , Cell Line, Tumor , Molecular Docking Simulation , Thiosemicarbazones/pharmacology , Thiosemicarbazones/chemistry , PPAR gamma , Drug Screening Assays, Antitumor , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Thiazolidinediones/pharmacology , Anti-Bacterial Agents/pharmacology , Molecular Structure , Cell Proliferation , Histone Deacetylases/metabolism , Repressor Proteins/metabolism
2.
Int J Mol Sci ; 24(3)2023 Jan 20.
Article in English | MEDLINE | ID: mdl-36768392

ABSTRACT

Two distinct intracellular pathogens, namely Mycobacterium tuberculosis (Mtb) and Toxoplasma gondii (Tg), cause major public health problems worldwide. In addition, serious and challenging health problems of co-infections of Tg with Mtb have been recorded, especially in developing countries. Due to this fact, as well as the frequent cases of resistance to the current drugs, novel anti-infectious therapeutics, especially those with dual (anti-Tg and anti-Mtb) modes of action, are needed. To address this issue, we explored the anti-Tg potential of thiazolidinedione-based (TZD-based) hybrid molecules with proven anti-Mtb potency. Several TZD hybrids with pyridine-4-carbohydrazone (PCH) or thiosemicarbazone (TSC) structural scaffolds were more effective and more selective than sulfadiazine (SDZ) and trimethoprim (TRI). Furthermore, all of these molecules were more selective than pyrimethamine (PYR). Further studies for the most potent TZD-TSC hybrids 7, 8 and 10 and TZD-PCH hybrid molecule 2 proved that these compounds are non-cytotoxic, non-genotoxic and non-hemolytic. Moreover, they could cross the blood-brain barrier (BBB), which is a critical factor linked with ideal anti-Tg drug development. Finally, since a possible link between Tg infection and the risk of glioblastoma has recently been reported, the cytotoxic potential of TZD hybrids against human glioblastoma cells was also evaluated. TZD-PCH hybrid molecule 2 was found to be the most effective, with an IC50 of 19.36 ± 1.13 µg/mL against T98G cells.


Subject(s)
Glioblastoma , Mycobacterium tuberculosis , Toxoplasma , Toxoplasmosis , Tuberculosis , Humans , Toxoplasmosis/drug therapy
3.
Bioorg Chem ; 133: 106398, 2023 04.
Article in English | MEDLINE | ID: mdl-36739686

ABSTRACT

Thiazolidin-4-one derivatives have a wide range of therapeutic implementations and clinical significance for medicinal chemistry. This heterocyclic ring has been reported to possess a variety of biological activities, including antiprotozoal activities that have inspired scientists to integrate this scaffold with different pharmacophoric fragments to design novel and effective antiprotozoal compounds. There are reviews describing thiazolidin-4-ones small molecules as good candidates with a single type of antiprotozoal activity, but none of these show collected news associated with the antiprotozoal activity of thiazolidin-4-ones and their SAR analysis from the last decade. In this review we are focusing on the antitoxoplasmic, anti-trypanosomal, antimalarial, antileishmanial, and antiamoebic activity of these derivatives, we attempt to summarize and analyze the recent developments with regard to the antiprotozoal potential of 4-TZD covering the structure-activity relationship and main molecular targets. The importance of various structural modifications at C2, N3, and C5 of the thiazolidine-4-one core has also been discussed in this review. We hope that all information concluded in this review can be useful for other researchers in constructing new effective antiprotozoal agents.


Subject(s)
Antimalarials , Antiprotozoal Agents , Antiprotozoal Agents/chemistry , Structure-Activity Relationship , Thiazolidines/chemistry , Antimalarials/pharmacology , Antimalarials/therapeutic use
4.
Int J Mol Sci ; 25(1)2023 Dec 26.
Article in English | MEDLINE | ID: mdl-38203498

ABSTRACT

Thiazolidin-4-ones have a broad range of medical and clinical implementation, which is important for pharmaceutical and medicinal chemistry. This heterocyclic core has been reported to possess a diversity of bioactivities, including antimicrobial and antibiofilm-forming potential. The resistance of biofilms to antibiotics or disinfectants is a serious medical problem. Therefore, there is a natural need to discover new effective structures with properties that inhibit biofilm formation. This review aims to analyze the antibiofilm features of thiazolidin-4-ones described in the literature over the last two decades. The information gathered in this review could benefit the rational design of new effective antibiofilm small molecules with thiazolidin-4-one cores.


Subject(s)
Anti-Bacterial Agents , Disinfectants , Anti-Bacterial Agents/pharmacology , Biofilms , Cell Aggregation , Chemistry, Pharmaceutical
5.
J Enzyme Inhib Med Chem ; 37(1): 2621-2634, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36165032

ABSTRACT

A safer treatment for toxoplasmosis would be achieved by improving the selectivity profile of novel chemotherapeutics compared to the standard therapy pyrimethamine (PYR) and sulfadiazine (SDZ). We previously reported on the identification of the compounds with imidazole-thiosemicarbazide scaffold as potent and selective anti-Toxoplasma gondii (T. gondii) agents. In our current research, we report on the optimisation of this chemical scaffold leading to the discovery cyclic analogue 20 b with s-triazole core structure. This compound displayed prominent CC30 to IC50 selectivity index (SI) of 70.72, making it 160-fold more selective than SDZ, 11-fold more selective than PYR, and 4-fold more selective than trimethoprim (TRI). Additionally, this compound possesses prerequisite drug-like anti-Toxoplasma properties to advance into preclinical development; it showed ability to cross the BBB, did not induce genotoxic and haemolytic changes in human cells, and as well as it was characterised by low cellular toxicity.


Subject(s)
Antiprotozoal Agents , Toxoplasma , Antiprotozoal Agents/pharmacology , Humans , Imidazoles , Pyrimethamine/pharmacology , Sulfadiazine/pharmacology , Sulfadiazine/therapeutic use , Triazoles/pharmacology , Trimethoprim
6.
Molecules ; 27(12)2022 Jun 10.
Article in English | MEDLINE | ID: mdl-35744873

ABSTRACT

The rhodanine core is a well-known privileged heterocycle in medicinal chemistry. The rhodanines, as subtypes of thiazolidin-4-ones, show a broad spectrum of biological activity, including anticancer properties. This review aims to analyze the anticancer features of the rhodanines described over the last decade in the scientific literature. The structure-activity relationship of rhodanine derivatives, as well as some of the molecular targets, were discussed. The information contained in this review could be of benefit to the design of new, effective small molecules with anticancer potential among rhodanine derivatives or their related heterocycles.


Subject(s)
Rhodanine , Chemistry, Pharmaceutical , Rhodanine/chemistry , Rhodanine/pharmacology , Structure-Activity Relationship
7.
Int J Mol Sci ; 22(21)2021 Oct 26.
Article in English | MEDLINE | ID: mdl-34768964

ABSTRACT

Thiazolidin-4-ones is an important heterocyclic ring system of a pharmacophore and a privileged scaffold in medicinal chemistry. This review is focused on the latest scientific reports regarding biological activities of thiazolidin-4-ones published in 2020 and 2021. The review covers recent information about antioxidant, anticancer, anti-inflammatory, analgesic, anticonvulsant, antidiabetic, antiparasitic, antimicrobial, antitubercular and antiviral properties of thiazolidin-4-ones. Additionally, the influence of different substituents in molecules on their biological activity was discussed in this paper. Thus, this study may help to optimize the structure of thiazolidin-4-one derivatives as more efficient drug agents. Presented information may be used as a practical hint for rational design of new small molecules with biological activity, especially among thiazolidin-4-ones.


Subject(s)
Thiazolidines/chemistry , Thiazolidines/pharmacology , Analgesics/chemistry , Analgesics/pharmacology , Animals , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Anticonvulsants/chemistry , Anticonvulsants/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antioxidants/chemistry , Antioxidants/pharmacology , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Molecular Structure , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Structure-Activity Relationship
8.
Eur J Med Chem ; 215: 113266, 2021 Apr 05.
Article in English | MEDLINE | ID: mdl-33588179

ABSTRACT

Thiazolidin-4-one scaffold has great potential for medicinal chemistry and is of interest to scientists in view of wide spectrum of biological activity. This scaffold is often used for designing of small molecules with various biological activity including antituberculosis activity. The presented review is an attempt to gather, analyze and systemize data about antitubercular properties of thiazolidine-4-ones from two last decades. Some of them have promising antitubercular activity which is significantly higher than that of the reference drugs. Among them compounds 82c, 82d and 84 that were active against M. tuberculosis H37Rv strain with MICs in the range of 0.05-0.2 µg/mL and compound 108 exhibited activity with MIC = 0.36 µM. Compounds 115a-115c and 116a-116c were very effective against M. tuberculosis H37Ra with MIC values in the range of 0.031-0.125 µg/mL. Acidomycin was showed activity against seven MDR M. tuberculosis strains with MICs in the range of 0.6-0.62 µM and against two XDR M. tuberculosis strains with MICs 0.096 and 1.2 µM. The structure-activity relationship (SAR) of some groups of compounds, as well as some potential molecular targets were also discussed.


Subject(s)
Antitubercular Agents/pharmacology , Thiazolidines/pharmacology , Animals , Antitubercular Agents/chemistry , Chlorocebus aethiops , Humans , Microbial Sensitivity Tests , Molecular Structure , Mycobacterium/drug effects , Structure-Activity Relationship , THP-1 Cells , Thiazolidines/chemistry , Vero Cells
9.
Molecules ; 25(10)2020 May 14.
Article in English | MEDLINE | ID: mdl-32422899

ABSTRACT

Antimicrobial resistance spurred by the overuse and misuse of antibiotics is a major global health concern, and of the Gram positive bacteria, S. aureus is a leading cause of mortality and morbidity. Alternative strategies to treat S. aureus infections, such as combination therapy, are urgently needed. In this study, a checkerboard method was used to evaluate synergistic interactions between nine thiosemicarbazides (4-benzoyl-1-(2,3-dichloro-benzoyl)thiosemicarbazides 1-5 and 4-aryl-1-(2-fluorobenzoyl)thiosemicarbazides 6-9) and conventional antibiotics against S. aureus ATCC 25923, which were determined as the fractional inhibitory concentration indices (FICIs). For these experiments, amoxicillin, gentamicin, levofloxacin, linezolid, and vancomycin were selected to represent the five antimicrobial classes most commonly used in clinical practice. With one exception of 7-vancomycin combination, none of the forty-five thiosemicarbazide-antibiotic combinations tested had an antagonistic effect, showing promising results with respect to a combination therapy. The synergic effect was observed for the 2-linezolid, 4-levofloxacin, 5-linezolid, 6-gentamicin, 6-linezolid, and 7-levofloxacin combinations. No interactions were seen in combination of the thiosemicarbazide with gentamicin or vancomycin, whereas all combinations with linezolid acted in additive or synergism, except for 6-gentamicin and 7-linezolid. The 4-(4-chlorophenyl)-1-(2-fluorobenzoyl)thiosemicarbazide 6 showed a clear preference for the potency; it affected synergistically in combinations with gentamicin or linezolid and additively in combinations with amoxicillin, levofloxacin, or vancomycin. In further studies, the inhibitory potency of the thiosemicarbazides against S. aureus DNA gyrase and topoisomerase IV was examined to clarify the molecular mechanism involved in their synergistic effect in combination with levofloxacin. The most potent synergist 6 at concentration of 100 µM was able to inhibit ~50% activity of S. aureus DNA gyrase, thereby suggesting that its anti-gyrase activity, although weak, may be a possible factor contributing to its synergism effect in combination with linezolid or gentamycin.


Subject(s)
Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Gentamicins/pharmacology , Levofloxacin/pharmacology , Linezolid/pharmacology , Semicarbazides/pharmacology , Staphylococcus aureus/drug effects , Vancomycin/pharmacology , Amoxicillin/chemistry , Anti-Bacterial Agents/chemistry , Cell Line , Cell Survival/drug effects , DNA Gyrase/genetics , DNA Gyrase/metabolism , DNA Topoisomerase IV/antagonists & inhibitors , DNA Topoisomerase IV/genetics , DNA Topoisomerase IV/metabolism , Drug Combinations , Drug Synergism , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/physiology , Gene Expression , Gentamicins/chemistry , Humans , Levofloxacin/chemistry , Linezolid/chemistry , Microbial Sensitivity Tests , Semicarbazides/chemistry , Staphylococcus aureus/enzymology , Staphylococcus aureus/genetics , Staphylococcus aureus/growth & development , Structure-Activity Relationship , Vancomycin/chemistry
10.
Bioorg Chem ; 97: 103676, 2020 04.
Article in English | MEDLINE | ID: mdl-32097795

ABSTRACT

The two series of thiosemicarbazone derivatives with thiazolidine-2,4-dione (TZD) core were designed and synthesized. The antimycobacterial activity of the target compounds was tested against Mycobacterium tuberculosis H37Ra by broth microdilution method with resazurin as an indicator of the metabolic activity of mycobacteria. Conducted studies revealed antimycobacterial activity in the concentration range of 0.031-64 µg/ml for 31 synthesized derivatives with TZD core. The highest antimycobacterial activity (MIC = 0.031-0.125 µg/ml) was demonstrated for the new group of compounds: TZD-based hybrids with 4-unsubstituted thiosemicarbazone substituent. Furthermore, all the tested compounds within this group were characterized by low cytotoxicity. Among tested compounds, two compounds are the most promising potential antimycobacterial agents since they not only show very low MIC values, but also non-toxicity against Vero cells at tested concentration range. High effectiveness and safety of these synthesized compounds makes them promising candidates as antimycobacterial agents.


Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Mycobacterium tuberculosis/drug effects , Thiazolidinediones/chemistry , Thiazolidinediones/pharmacology , Thiosemicarbazones/chemistry , Thiosemicarbazones/pharmacology , Animals , Antitubercular Agents/chemical synthesis , Chlorocebus aethiops , Drug Design , Humans , Thiazolidinediones/chemical synthesis , Thiosemicarbazones/chemical synthesis , Tuberculosis/drug therapy , Vero Cells
11.
Eur J Med Chem ; 189: 112045, 2020 Mar 01.
Article in English | MEDLINE | ID: mdl-31951961

ABSTRACT

The two series of thiazolidine-2,4-dione (TZD) based hybrids with halogenbenzohydrazones and pyridinecarbohydrazones substituents were designed and synthesized. Target hydrazones were evaluated for their antimycobacterial activity by broth microdilution method with resazurin as an indicator of the metabolic activity of mycobacteria. Conducted studies revealed antimycobacterial activity in the concentration range of 1-512 µg/ml for 23 synthesized TZD-based derivatives. The highest antimycobacterial activity (MIC = 1 µg/ml) was demonstrated for the new group of compounds: TZD-based derivatives with pyridine-4-carbohydrazone substituent. Furthermore, all the tested compounds within this group were characterized by low cytotoxicity. On the basis of the results obtained, three compounds with the highest SI were selected. High effectiveness and safety of these synthesized derivatives makes them promising candidates as antimycobacterial agents.


Subject(s)
Antitubercular Agents/pharmacology , Hydrazones/pharmacology , Thiazolidinediones/pharmacology , Animals , Antitubercular Agents/chemical synthesis , Chlorocebus aethiops , Drug Design , Hydrazones/chemical synthesis , Microbial Sensitivity Tests , Molecular Structure , Mycobacterium tuberculosis/drug effects , Thiazolidinediones/chemical synthesis , Vero Cells
12.
Molecules ; 26(1)2020 Dec 31.
Article in English | MEDLINE | ID: mdl-33396536

ABSTRACT

The development of drug-resistant bacteria is currently one of the major challenges in medicine. Therefore, the discovery of novel lead structures for the design of antibacterial drugs is urgently needed. In this structure-activity relationship study, a library of ortho-, meta-, and para-fluorobenzoylthiosemicarbazides, and their cyclic analogues with 1,2,4-triazole scaffold, was created and tested for antibacterial activity against Gram-positive bacteria strains. While all tested 1,2,4-triazoles were devoid of potent activity, the antibacterial response of the thiosemicarbazides was highly dependent on substitution pattern at the N4 aryl position. The optimum activity for these compounds was found for trifluoromethyl derivatives such as 15a, 15b, and 16b, which were active against both the reference strains panel, and pathogenic methicillin-sensitive and methicillin-resistant Staphylococcus aureus clinical isolates at minimal inhibitory concentrations (MICs) ranging from 7.82 to 31.25 µg/mL. Based on the binding affinities obtained from docking, the conclusion can be reached that fluorobenzoylthiosemicarbazides can be considered as potential allosteric d-alanyl-d-alanine ligase inhibitors.


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Semicarbazides/chemistry , Staphylococcus aureus/drug effects , Triazoles/chemistry , Microbial Sensitivity Tests , Structure-Activity Relationship
13.
Molecules ; 24(17)2019 Aug 21.
Article in English | MEDLINE | ID: mdl-31438527

ABSTRACT

Recent findings on the biological activity of thiazolidin-4-ones and taking into account the lack of effective drugs used in the treatment of toxoplasmosis, their numerous side effects, as well as the problem of drug resistance of parasites prompted us to look for new agents. We designed and synthesized a series of new thiazolidin-4-one derivatives through a two-step reaction between 4-substituted thiosemicarbazides with hydroxybenzaldehydes followed by the treatment with ethyl bromoacetate; maleic anhydride and dimethyl acetylenedicarboxylate afforded target compounds. The thiazolidin-4-one derivatives were used to assess the inhibition of Toxoplasma gondii growth in vitro. All active thiazolidine-4-one derivatives (12 compounds) inhibited T. gondii proliferation in vitro much better than used references drugs both sulfadiazine as well as the synergistic effect of sulfadiazine + trimethoprim (weight ratio 5:1). Most active among them derivatives 94 and 95 showed inhibition of proliferation at about 392-fold better than sulfadiazine and 18-fold better than sulfadiazine with trimethoprim. All active compounds (82-88 and 91-95) against T. gondii represent values from 1.75 to 15.86 (CC30/IC50) lower than no cytotoxic value (CC30).


Subject(s)
Antiprotozoal Agents/therapeutic use , Sulfadiazine/therapeutic use , Toxoplasma/drug effects , Trimethoprim/therapeutic use , Animals , Antiprotozoal Agents/chemistry , Cell Line , Cell Survival/drug effects , Drug Combinations , Humans , Magnetic Resonance Spectroscopy , Mice , Structure-Activity Relationship , Sulfadiazine/chemistry , Thiosemicarbazones/therapeutic use , Toxoplasmosis
14.
Chem Biodivers ; 16(10): e1900377, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31436917

ABSTRACT

The series of novel Mannich bases were synthesized and evaluated for their in vitro antibacterial activity against Gram-positive and Gram-negative bacterial strains. The results showed that all compounds were less active than the drugs used as reference, but some of them had moderate potency against Staphylococcus epidermidis ATCC 12228 and Bacillus subtilis ATCC 6633. The presence of a phenyl ring in the position 4 of piperazine seems to be necessary for antibacterial activity in this class of compounds.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacillus subtilis/drug effects , Mannich Bases/chemistry , Staphylococcus epidermidis/drug effects , Triazoles/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Microbial Sensitivity Tests , Molecular Structure , Triazoles/chemical synthesis , Triazoles/chemistry
15.
Molecules ; 24(8)2019 Apr 24.
Article in English | MEDLINE | ID: mdl-31022878

ABSTRACT

Employing a simple synthetic protocol, a series of highly effective halogen-substituted imidazole-thiosemicarbazides with anti-Toxoplasma gondii effects against the RH tachyzoites, much better than sulfadiazine, were obtained (IC50s 10.30-113.45 µg/mL vs. ~2721.45 µg/mL). The most potent of them, 12, 13, and 15, blocked the in vitro proliferation of T. gondii more potently than trimethoprim (IC50 12.13 µg/mL), as well. The results of lipophilicity studies collectively suggest that logP would be a rate-limiting factor for the anti-Toxoplasma activity of this class of compounds.


Subject(s)
Semicarbazides/chemical synthesis , Structure-Activity Relationship , Toxoplasma/drug effects , Toxoplasmosis/drug therapy , Animals , Halogens/chemistry , Humans , Imidazoles/chemistry , Imidazoles/pharmacology , Semicarbazides/chemistry , Sulfadiazine/pharmacology , Toxoplasma/pathogenicity , Toxoplasmosis/parasitology
16.
Molecules ; 24(6)2019 Mar 17.
Article in English | MEDLINE | ID: mdl-30884874

ABSTRACT

Biofilm, naturally formed by microorganisms as integrated surface-bound communities, is one of the reasons for the development of antimicrobial resistance. Haemophilus spp. are common and representative opportunistic Gram-negative rods forming from the upper respiratory tract microbiota. The aim of this paper was to evaluate the influence of thiazolidine-2,4-dionebased azolidine and chlorophenylthiosemicarbazone hybrids against both planktonic and biofilm-forming Haemophilus spp. cells. The in vitro activity against planktonic and biofilm-forming cells of the tested compounds were evaluated by using the broth microdilution method. These activities were detected against reference and clinical strains of Haemophilus spp. on the basis of MICs (minimal inhibitory concentrations) and MBICs (minimal biofilm inhibitory concentrations). In addition, anti-adhesive properties of these compounds were examined. The target compounds showed potential activity against planktonic cells with MIC = 62.5⁻500 mg/L and biofilm-forming cells with MBIC = 62.5⁻1000 mg/L. The observed anti-adhesive properties of the tested compounds were reversible during long-term incubation in a lower concentration of compounds.


Subject(s)
Anti-Bacterial Agents/chemistry , Biofilms/drug effects , Haemophilus/drug effects , Thiosemicarbazones/chemistry , Anti-Bacterial Agents/pharmacology , Biofilms/growth & development , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/pathogenicity , Haemophilus/growth & development , Microbial Sensitivity Tests , Plankton/drug effects , Thiazolidinediones/chemistry , Thiazolidinediones/pharmacology , Thiosemicarbazones/pharmacology
17.
Molecules ; 24(3)2019 Feb 10.
Article in English | MEDLINE | ID: mdl-30744161

ABSTRACT

One of the key stages in the development of new therapies in the treatment of toxoplasmosis is the identification of new non-toxic small molecules with high specificity to Toxoplasma gondii. In the search for such structures, thiosemicarbazide-based compounds have emerged as a novel and promising leads. Here, a series of imidazole-thiosemicarbazides with suitable properties for CNS penetration was evaluated to determine the structural requirements needed for potent anti-Toxoplasma gondii activity. The best 4-arylthiosemicarbazides 3 and 4 showed much higher potency when compared to sulfadiazine at concentrations that are non-toxic to the host cells, indicating a high selectivity of their anti-toxoplasma activity.


Subject(s)
Antiparasitic Agents/pharmacology , Drug Evaluation, Preclinical , Semicarbazides/pharmacology , Toxoplasma/drug effects , Animals , Antiparasitic Agents/chemistry , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Humans , Inhibitory Concentration 50 , Models, Molecular , Molecular Conformation , Molecular Structure , Parasitic Sensitivity Tests , Semicarbazides/chemistry , Structure-Activity Relationship , Toxoplasmosis/drug therapy , Toxoplasmosis/parasitology
18.
Saudi Pharm J ; 26(4): 568-577, 2018 May.
Article in English | MEDLINE | ID: mdl-29844729

ABSTRACT

A series of new (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid derivatives with thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin moiety (28-65) were synthesized by the reaction of (2,4-dioxothiazolidin-5-yl/ylidene)acetic acid chlorides with 5-(hydroxybenzylidene) thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin derivatives. Obtained compounds (28-65) were tested on reference strains of Gram-positive bacteria and ones of the Gram-negative bacteria. The antibacterial activity of target compounds was determined by broth microdilution method. These derivatives showed antibacterial activity generally against Gram-positive bacterial strains. Most active compounds possess MIC = 3.91 mg/L. Our results suggest that presence of electron-withdrawing substituent at phenyl ring is favorable while geometry of molecule does not play important role in antibacterial response. It was confirmed the lack of direct influence of substitution pattern at phenyl ring on antibacterial activity of closely related compounds of series 1-3. The antibacterial activity of some compounds was similar or higher than the activity of commonly used reference drugs such as oxacillin and cefuroxime.

19.
Molecules ; 23(5)2018 Apr 26.
Article in English | MEDLINE | ID: mdl-29701728

ABSTRACT

Series of new thiazolidine-2,4-dione-based chlorophenylthiosemicarbazone hybrids (17⁻40) were synthesized by the reaction of condensation chlorophenylthiosemicarbazides with formylphenyl 2-(2,4-dioxothiazolidin-5-yl/ylidene)acetates. New compounds were tested on reference strains of Gram-positive and Gram-negative bacteria. The antibacterial activity of target compounds was determined by broth dilution method. Most active compounds possess minimum inhibitory concentration (MIC) = 3.91 mg/L. These compounds were non-toxic at concentrations close to their antibacterial effect. The antibacterial activity of some compounds was similar to or higher than the activity of used reference drugs such as oxacillin and cefuroxime. The structure⁻activity relationships (SARs) analysis collectively suggests that at least two different molecular mechanisms of their antibacterial activity should be expected.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Sulfur Compounds/chemical synthesis , Thiazolidinediones/chemistry , Thiosemicarbazones/chemistry , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity Relationship , Sulfur Compounds/chemistry , Sulfur Compounds/pharmacology
20.
J Enzyme Inhib Med Chem ; 33(1): 17-24, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29098896

ABSTRACT

In our present research, we synthesised new thiazolidine-2,4-diones (12-28). All the newly synthesised compounds were evaluated for antiproliferative and antibacterial activity. Antiproliferative evaluation was carried out using normal human skin fibroblasts and tumour cell lines: A549, HepG2, and MCF-7. The IC50 values were determined for tested compounds revealing antiproliferative activity. Moreover, safety index (SI) was calculated. Among all tested derivatives, the compound 18 revealed the highest antiproliferative activity against human lung, breast, and liver cancer cells. More importantly, the derivative 18 showed meaningfully lower IC50 values when compared to the reference substance, irinotecan, and relatively high SI values. Moreover, newly synthesised compounds were screened for the bacteria growth inhibition in vitro. According to our screening results, most active compound was the derivative 18 against Gram-positive bacteria. Therefore, it may be implied that the novel compound 18 appears to be a very promising agent for anticancer treatment.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Thiazolidinediones/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Gram-Negative Bacteria/cytology , Gram-Negative Bacteria/growth & development , Gram-Positive Bacteria/cytology , Gram-Positive Bacteria/growth & development , Humans , Microbial Sensitivity Tests , Molecular Docking Simulation , Molecular Structure , Structure-Activity Relationship , Thiazolidinediones/chemical synthesis , Thiazolidinediones/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...